How Many Americans May Be Living With Long Flu? US-CCUC Influenza™ Estimates Hidden Post-Influenza Chronic Illness
- 1 day ago
- 29 min read
The recent influenza outbreak among military trainees at Joint Base San Antonio-Lackland highlights a growing public health question: while outbreaks are measured in infections and hospitalizations, how many people continue experiencing health problems after the outbreak ends?
By: Cynthia Adinig
Influenza™ Estimates Hidden Post-Influenza Chronic Illness
Summary
Seasonal influenza has traditionally been measured through infections, hospitalizations, and mortality. These metrics remain essential for outbreak detection and public health response, yet they capture only part of influenza's total health burden. Once the acute infection has resolved, routine surveillance rarely follows patients long enough to determine whether they return fully to their previous physiological baseline. As a result, persistent post-infectious health consequences may remain substantially underrecognized.
Recent influenza outbreaks, including the outbreak affecting military trainees at Joint Base San Antonio-Lackland, have renewed attention on the immediate operational impacts of influenza. Public health systems rapidly identified the outbreak, implemented infection control measures, and monitored acute clinical outcomes. Far less is known, however, about how many affected individuals continue experiencing fatigue, cognitive dysfunction, exercise intolerance, autonomic symptoms, respiratory limitations, or other persistent health effects months after the outbreak has ended. This recovery gap reflects a broader limitation of modern infectious disease surveillance.
US-CCUC™ Influenza applies CYNAERA's United States Chronic Condition Undercount Correction (US-CCUC™ ) methodology to estimate the hidden population living with persistent post-influenza chronic illness. Rather than relying on any single surveillance source, the framework integrates influenza burden estimates, longitudinal outcome studies, healthcare utilization patterns, patient-reported outcomes, biological evidence, and established surveillance correction principles to estimate the population that remains incompletely visible after routine influenza surveillance concludes.
Unlike previous approaches, this paper distinguishes between the historical pre-pandemic burden of post-influenza chronic illness and the contemporary post-pandemic environment. The framework recognizes that influenza now circulates within a substantially different biological landscape following widespread SARS-CoV-2 infection and the expansion of infection-associated chronic conditions (IACCs), including Long COVID, ME/CFS, dysautonomia, and autoimmune disease.
Using conservative planning assumptions, US-CCUC™ Influenza estimates that approximately 600,000 to 900,000 Americans were living with persistent post-influenza chronic illness during the pre-pandemic era. Under contemporary post-pandemic conditions, the estimated planning population increases to approximately 1.2 to 1.8 million Americans. Applying evidence-informed healthcare planning costs suggests that this hidden population may represent an estimated $6 billion to $27 billion in annual healthcare and economic impact, with a moderate planning estimate of approximately $15 billion per year.
This paper also introduces MORALE™ (Military Outbreak Recovery Assessment for Long-term Effects), a recovery forecasting framework that extends disease intelligence from estimating hidden prevalence to forecasting the downstream recovery population following infectious disease outbreaks. Using the recent Joint Base San Antonio-Lackland influenza outbreak as an illustrative example, MORALE™ demonstrates how outbreak investigations can be expanded beyond acute case counts to estimate delayed recovery, persistent symptoms, and potential long-term post-infectious illness.
The recent influenza outbreak among military trainees at Joint Base San Antonio-Lackland, which was followed by the reinstatement of mandatory influenza vaccination for military recruits, renewed national discussion about military influenza vaccination policy while highlighting the need for a broader approach to outbreak preparedness. Much of the public conversation has focused on population-level protection versus individualized medical decision-making.
Recovery-aware public health introduces an additional question: How can healthcare systems better identify when medically complex individuals are physiologically prepared for immune intervention while also strengthening outbreak prevention and long-term recovery planning?
Within the broader CYNAERA ecosystem, Va-IRI™ (Vaccination Immune Readiness Index) and the Adaptive Vaccination Protocol™ (AVP™) explore individualized readiness and adaptive vaccination strategies for immune-fragile populations. Rather than replacing existing vaccination recommendations, these complementary frameworks seek to add a biologically informed layer to clinical decision-making by evaluating physiologic stability, immune readiness, and individualized risk. Together with US-CCUC™ Influenza, REVIVE™, and MORALE™, they illustrate how recovery intelligence can extend from population surveillance and outbreak forecasting to personalized clinical decision support.
Key Findings
Traditional influenza tracking primarily measures acute disease. Infections, hospitalizations, and mortality are routinely tracked, while long-term recovery is rarely measured.
Persistent illness following influenza has been described for more than a century. Historical and contemporary evidence suggests that prolonged post-infectious illness is not unique to COVID-19.
US-CCUC™ Influenza applies a recovery-aware surveillance framework. The methodology integrates multiple evidence streams to estimate hidden post-influenza chronic illness rather than relying solely on diagnosed cases.
The biological landscape has changed since 2020. Millions of Americans now live with Long COVID and other infection-associated chronic conditions that may influence recovery following subsequent infections.
Estimated historical burden: Approximately 600,000 to 900,000 Americans were living with persistent post-influenza chronic illness before the COVID-19 pandemic.
Estimated contemporary burden: Approximately 1.2 to 1.8 million Americans are living with persistent post-influenza chronic illness or clinically significant post-influenza health impairment.
Recent military influenza outbreaks highlight the need for recovery-aware surveillance. Current systems effectively measure acute outbreak response but provide limited information regarding long-term recovery.
Corrected prevalence supports healthcare planning. Improved estimates may strengthen rehabilitation planning, specialty care capacity, disability forecasting, military readiness, workforce planning, and pandemic preparedness.
US-CCUC™ complements rather than replaces existing influenza surveillance. The framework extends observation beyond acute infection to estimate the hidden population living with prolonged illness after influenza.
Can Influenza Cause Long-Term Illness?
Recent influenza outbreaks, including the large outbreak among military trainees at Joint Base San Antonio-Lackland, illustrate both the strengths and limitations of modern influenza surveillance. Public health officials rapidly identified the outbreak, implemented infection control measures, monitored hospitalizations, and evaluated vaccination and operational readiness. These actions represent exactly what influenza surveillance was designed to accomplish. Yet once the acute outbreak subsides, a different question emerges: how many of those individuals will still be experiencing health consequences months from now?
At present, no routine national surveillance system is specifically designed to answer that question. Once patients recover from the acute infection or leave the hospital, longitudinal recovery is rarely followed unless they enroll in a dedicated research study. Individuals who later develop fatigue, cognitive impairment, exercise intolerance, autonomic dysfunction, respiratory limitations, or other persistent symptoms often enter entirely different areas of the healthcare system where the original influenza infection may no longer be recognized as the initiating event.
US-CCUC™ Influenza was developed to estimate that hidden recovery population. It extends CYNAERA's United States Chronic Condition Undercount Correction (US-CCUC™) methodology, which estimates disease populations that remain incompletely visible because surveillance systems naturally prioritize acute illness over long-term recovery. Rather than relying on a single dataset, the framework integrates multiple layers of healthcare visibility, including laboratory-confirmed infections, hospitalization data, longitudinal outcome studies, healthcare utilization patterns, patient-reported outcomes, biological evidence, and administrative diagnosis data. Each source captures one portion of the disease process. Together, they provide a more complete estimate of the population living with persistent post-infectious illness.
US-CCUC™ functions within CYNAERA's broader Infection-Associated Chronic Condition (IACC) framework, which recognizes that acute infections can initiate or worsen chronic disease through multiple biological pathways. Within this ecosystem, the Primary Chronic Trigger (PCT™) Framework identifies infections, environmental exposures, and other major biological events that may initiate long-term illness. Stage Zero™ describes the period of physiological instability that may precede formal diagnosis, when measurable dysfunction exists before conventional diagnostic thresholds are reached. Adaptive Reserve Collapse™ (ARC™) proposes that repeated biological stressors, inadequate recovery, and cumulative physiological burden gradually reduce an individual's capacity to return to baseline following subsequent insults. US-CCUC™ complements these frameworks by estimating the portion of the affected population that remains hidden because existing surveillance systems conclude once the acute infection has resolved.
From this perspective, influenza should not be viewed solely as an acute respiratory illness but as one potential trigger within the broader landscape of infection-associated chronic conditions. Long before Long COVID entered the medical literature, many individuals diagnosed with ME/CFS described their illness as beginning after a severe influenza or influenza-like illness (Institute of Medicine, 2015; Komaroff and Lipkin, 2023). Similar post-infectious syndromes have also been described following Epstein-Barr virus, Lyme disease, Q fever, dengue, Ebola, enteroviruses, and numerous other pathogens (Choutka et al., 2022). These observations do not imply that every patient develops chronic illness after influenza or that influenza produces outcomes comparable to SARS-CoV-2. Rather, they demonstrate that persistent post-infectious illness has long been recognized across multiple pathogens and that recovery is influenced by both the infectious agent and the biological terrain of the host.
The COVID-19 pandemic has made this distinction increasingly important. Millions of Americans now live with Long COVID, dysautonomia, ME/CFS, autoimmune diseases, and other infection-associated chronic conditions. Influenza therefore circulates within a substantially different population than existed before 2020. For some individuals, influenza may represent a primary initiating event. For others, it may act as a secondary destabilizing trigger that prolongs recovery, worsens existing illness, or contributes to cumulative physiological stress.
US-CCUC™ Influenza was developed to estimate this changing landscape by extending surveillance beyond infections, hospitalizations, and mortality toward the outcome that ultimately matters most to patients: whether they return to their previous physiological baseline.
Why Some People Never Fully Recover From Influenza
Traditional influenza surveillance was developed to answer a fundamentally important public health question: how many people became acutely ill? To accomplish this, surveillance systems track laboratory-confirmed infections, outpatient visits, emergency department utilization, hospitalizations, intensive care admissions, mortality, circulating viral strains, and vaccine effectiveness. These metrics have substantially improved understanding of influenza epidemiology and remain essential for outbreak detection, seasonal forecasting, and pandemic preparedness (CDC, 2025; Reed et al., 2015).
A different but equally important question receives far less attention: how many people fail to fully recover after influenza infection? Unlike infections or hospitalizations, recovery is rarely measured systematically. Once the acute infectious period ends, most influenza surveillance systems conclude, leaving little visibility into the months that follow. Individuals who experience persistent fatigue, exercise intolerance, cognitive dysfunction, autonomic symptoms, respiratory limitations, chronic pain, or generalized functional decline frequently transition into primary care, rehabilitation, pulmonology, neurology, cardiology, rheumatology, or other specialties where the relationship to the original influenza infection may no longer be explicitly recognized.
This limitation reflects the design of surveillance systems rather than a failure of clinical care. Influenza surveillance was never intended to longitudinally follow every patient until complete physiological recovery. Instead, it was optimized to measure transmission, characterize seasonal severity, identify circulating viral strains, evaluate vaccine performance, and monitor immediate healthcare utilization. Consequently, patients who experience prolonged recovery gradually become less visible within influenza surveillance even though they remain active participants within the healthcare system.
Historical evidence suggests this phenomenon is not unique to the modern era. Medical literature dating back to the nineteenth century contains descriptions of prolonged fatigue, neurological dysfunction, cognitive impairment, autonomic symptoms, and chronic disability following influenza epidemics (Honigsbaum, 2024). More recently, Choutka and colleagues proposed that post-acute infection syndromes represent a broader biological phenomenon affecting numerous viral and bacterial pathogens rather than one unique to SARS-CoV-2 (Choutka et al., 2022).
Likewise, Al-Aly and colleagues demonstrated that patients hospitalized with seasonal influenza continued to experience elevated risks of death, hospital readmission, and multisystem health complications for up to eighteen months following infection, although overall risks remained greater following COVID-19 (Xie, Choi and Al-Aly, 2024).
The COVID-19 pandemic fundamentally changed how these observations are interpreted. Prior to 2020, persistent illness following infection was frequently viewed as an uncommon or poorly understood complication. Long COVID demonstrated instead that acute respiratory viruses can produce substantial long-term morbidity at the population level and highlighted the limitations of surveillance systems focused primarily on acute outcomes (Davis et al., 2021; Davis et al., 2023; National Academies of Sciences, Engineering, and Medicine, 2024). Rather than introducing a new biological phenomenon, Long COVID brought renewed attention to a longstanding surveillance gap shared across many infection-associated chronic conditions.
US-CCUC™ Influenza begins with this recovery-centered perspective. Rather than asking only how many individuals became infected during a given influenza season, the framework also asks how many failed to return to their previous physiological baseline. By treating recovery as a measurable public health outcome rather than an assumed endpoint, US-CCUC™ extends influenza surveillance beyond acute infection and provides a structured approach for estimating the hidden population living with persistent post-influenza chronic illness.
Why Has Long Flu Been Hidden Until Now?
The apparent absence of Long Flu from routine public health discussions does not necessarily mean that persistent post-influenza illness has been rare. Rather, it may reflect how infectious diseases have traditionally been measured. Influenza surveillance has historically focused on infections, emergency department visits, hospitalizations, and mortality because these indicators are essential for monitoring seasonal outbreaks and guiding immediate public health response (Reed et al., 2015; CDC, 2025; Iuliano et al., 2018). Once the acute infection resolves, however, routine surveillance generally ends. Most healthcare systems do not systematically follow influenza patients for months or years to determine whether they fully recover, continue experiencing persistent symptoms, or develop chronic health conditions (Choutka et al., 2022; National Academies of Sciences, Engineering, and Medicine, 2024).
Corrected prevalence is therefore more than an epidemiologic exercise. Nearly every major healthcare decision begins with an estimate of how many people are expected to require care. Health systems forecast staffing requirements, rehabilitation capacity, specialty clinic demand, pharmaceutical development, disability programs, insurance expenditures, military readiness, and public health resources using projected population size rather than confirmed diagnoses alone. When surveillance systematically underestimates the number of individuals living with persistent illness, planning systems are also likely to underestimate downstream healthcare demand (Adinig, US-CCUC, 2026).
The COVID-19 pandemic demonstrated the consequences of delayed recognition. Long COVID clinics, rehabilitation programs, disability policies, clinical practice guidance, and research funding largely expanded only after millions of patients had already accumulated within healthcare systems. Earlier recognition of the post-acute disease burden may have accelerated research, improved healthcare planning, and reduced delays in diagnosis and clinical management (Davis et al., 2023; National Academies of Sciences, Engineering, and Medicine, 2024; Al-Aly et al., 2024). One of the central lessons of the pandemic is that measuring infections alone is insufficient when a proportion of patients experience prolonged recovery.
Recent influenza outbreaks reinforce the importance of applying that lesson proactively. Outbreak investigations appropriately focus on limiting transmission, protecting vulnerable populations, maintaining healthcare capacity, and restoring operational readiness. The recent outbreak among military trainees at Joint Base San Antonio-Lackland illustrates this approach. Public health officials rapidly characterized the outbreak, implemented infection control measures, and monitored acute clinical outcomes. Yet once the outbreak concluded, routine surveillance provided little information about how many affected individuals continued experiencing fatigue, exercise intolerance, cognitive symptoms, autonomic dysfunction, or other persistent health effects weeks or months later (CIDRAP, 2026; ABC News, 2026; Associated Press, 2026).
Although only a relatively small proportion of influenza infections may result in prolonged illness, influenza affects tens of millions of Americans during many seasons (CDC, 2026). Even conservative estimates of incomplete recovery therefore translate into substantial planning populations requiring ongoing healthcare, workplace accommodations, rehabilitation services, specialty evaluation, or disability support. From a healthcare systems perspective, small percentages applied to very large populations can produce meaningful downstream demand.
US-CCUC™ Influenza was developed to address this visibility gap by extending surveillance beyond acute infection. Rather than relying solely on reported influenza cases, the framework integrates evidence from influenza burden estimates, longitudinal recovery studies, post-infectious illness research, healthcare utilization patterns, and surveillance correction principles to estimate the hidden population living with persistent post-influenza chronic illness (Adinig, US-CCUC, 2026; Choutka et al., 2022; Reed et al., 2015). As understanding of infection-associated chronic conditions continues to evolve, measuring recovery may become as important to future public health preparedness as measuring transmission itself.
How Many Americans May Be Living With Long Flu?
US-CCUC™ Influenza estimates the hidden population living with persistent post-influenza chronic illness by distinguishing between the historical pre-pandemic burden and the contemporary post-pandemic burden. This distinction reflects a fundamental change in the biological terrain of the U.S. population rather than an assumption that influenza itself has fundamentally changed as a pathogen. Millions of Americans now live with Long COVID, ME/CFS, dysautonomia, autoimmune disease, and other infection-associated chronic conditions that may influence physiological reserve, immune recovery, and resilience following subsequent infections (Adinig, US-CCUC, 2026; Adinig, PCT Framework, 2026; Al-Aly et al., 2024).
Like CDC influenza burden estimates, US-CCUC™ Influenza recognizes that reported influenza cases substantially underestimate the true number of infections. The CDC therefore models seasonal influenza burden by incorporating under-ascertainment, healthcare utilization, and surveillance adjustments rather than relying solely on laboratory-confirmed diagnoses (Reed et al., 2015; CDC, 2025; CDC, 2026). US-CCUC™ extends this same surveillance correction philosophy beyond the acute phase by estimating the population that remains chronically affected after routine influenza surveillance has ended (Adinig, US-CCUC, 2026).
The framework estimates living prevalence using three core variables:
Estimated Living Prevalence = Annual Influenza Infections × Persistent Illness Probability × Average Illness Duration
Each component represents a measurable planning variable.
Annual influenza infections represent the total exposed population using CDC burden estimates rather than laboratory-confirmed case counts.
Persistent illness probability represents the proportion of infected individuals who continue experiencing clinically meaningful health impairment beyond expected recovery.
Average illness duration reflects the average period individuals remain within the post-infectious population before recovery, stabilization, or transition into another chronic disease category.
Historical Pre-Pandemic Estimate
For the historical pre-pandemic period, US-CCUC™ applies a moderate annual influenza illness range of 30 to 36 million infections, a conservative persistent illness probability of 1.0%, and an average illness duration of 2.0 to 2.5 years.
Low estimate
30 million × 1.0% × 2.0 years = 600,000 Americans
High estimate
36 million × 1.0% × 2.5 years = 900,000 Americans
Accordingly, US-CCUC™ estimates that approximately 600,000 to 900,000 Americans were living with persistent post-influenza chronic illness during the pre-pandemic era.
Contemporary Post-Pandemic Estimate
The post-pandemic environment represents a substantially different epidemiologic context. Influenza now circulates within a population that includes millions of individuals living with Long COVID, immune dysregulation, autonomic dysfunction, endothelial abnormalities, and reduced physiological reserve following SARS-CoV-2 infection (Davis et al., 2023; National Academies of Sciences, Engineering, and Medicine, 2024; Al-Aly et al., 2024). While influenza itself has not fundamentally changed, the host population has.
For the contemporary period, the framework therefore applies an annual influenza illness range of 34 to 51 million infections, a persistent illness probability of 1.5%, and an average illness duration of 2.3 years.
Low estimate
34 million × 1.5% × 2.3 years = 1.17 million Americans
High estimate
51 million × 1.5% × 2.3 years = 1.76 million Americans
Accordingly, US-CCUC™ estimates that approximately 1.2 to 1.8 million Americans may currently be living with persistent post-influenza chronic illness or clinically significant post-influenza health impairment.
Estimated Americans Living With Long Flu
Time Period | Estimated Annual Influenza Infections | Persistent Illness Probability | Estimated Living Long Flu Population |
Pre-2020 | 30–36 million | 1.0% | 600,000–900,000 |
Post-2020 | 34–51 million | 1.5% | 1.2–1.8 million |
These estimates should be interpreted as planning populations rather than definitive prevalence counts. The assumptions are intentionally conservative and remain substantially lower than commonly reported Long COVID prevalence estimates. The objective is not to equate influenza with SARS-CoV-2, but to demonstrate that even relatively low rates of prolonged recovery produce meaningful hidden populations when seasonal influenza affects tens of millions of Americans each year.
Separating historical and contemporary estimates avoids combining two biologically distinct eras into a single overly broad prevalence range. More importantly, it reflects one of the central principles of the CYNAERA Disease Intelligence ecosystem: the long-term consequences of infection are shaped not only by the characteristics of the pathogen, but also by the biological terrain of the population experiencing it (Adinig, PCT Framework, 2026; Adinig, US-CCUC, 2026).
The Hidden Economic Impact of Long Flu
Estimating how many Americans may be living with Long Flu is only the first step toward understanding its public health significance. Healthcare systems, employers, insurers, military planners, and policymakers ultimately plan around anticipated healthcare utilization, rehabilitation demand, disability programs, workforce participation, and long-term expenditures rather than prevalence estimates alone. Even relatively modest rates of prolonged recovery can translate into substantial economic consequences when seasonal influenza affects tens of millions of Americans each year (CDC, 2026; Reed et al., 2015).
CYNAERA's previous US-CCUC Military™ and PCT Military™ frameworks demonstrated how corrected prevalence estimates can be translated into practical healthcare planning scenarios. Those analyses used conservative annual planning costs of approximately $5,000 per affected individual, with broader chronic care estimates ranging from $6,000 to $15,000 annually for more medically complex populations (Adinig, US-CCUC Military, 2026; Adinig, PCT Military, 2026). Although those estimates were developed for military healthcare planning rather than Long Flu specifically, they provide an evidence-informed framework for illustrating how hidden prevalence may translate into downstream healthcare demand.
Applying those planning assumptions to the rounded planning estimate of 1.2 to 1.8 million Americans living with persistent post-influenza chronic illness produces the following annual planning estimates.
Planning Scenario | Annual Cost per Person | Rounded Planning Population | Estimated Annual Economic Impact |
Conservative | $5,000 | 1.2 million | $6.0 billion |
Moderate | $10,000 | 1.5 million | $15.0 billion |
High | $15,000 | 1.8 million | $27.0 billion |
Estimated Annual Planning Impact
Estimated Americans Living with Long Flu: 1.2-1.8 million
Estimated Annual Economic Impact: $6-27 billion
Moderate Planning Estimate: Approximately $15 billion annually
These estimates should be interpreted as planning projections rather than precise economic accounting. The rounded planning populations are intended to support healthcare forecasting and policy analysis rather than represent exact prevalence counts. They primarily reflect direct healthcare planning assumptions and do not include indirect costs such as reduced workforce participation, absenteeism, presenteeism, caregiver burden, disability benefits, educational disruption, lost household income, or long-term reductions in productivity. Consequently, the overall societal impact of persistent post-influenza illness may be substantially higher.
Importantly, these estimates demonstrate why relatively small percentages matter. A persistent illness probability of only 1.5% may appear modest at the individual level, yet when applied to 34 to 51 million influenza infections each year, it produces a hidden planning population of approximately 1.2 to 1.8 million Americans. From a public health perspective, small percentages applied to very large populations can generate substantial healthcare demand.
Economic planning also illustrates why recovery should be measured alongside transmission. Traditional influenza surveillance effectively estimates infections, hospitalizations, and mortality, but those metrics alone do not capture the downstream healthcare utilization associated with prolonged recovery. Recovery-aware surveillance extends public health planning beyond outbreak response by estimating the healthcare, rehabilitation, disability, workforce, and operational resources that may be required after acute transmission has ended.
The national estimates presented here provide the population-level context for Long Flu. The following section introduces MORALE™ (Military Outbreak Recovery Assessment for Long-term Effects), demonstrating how the same recovery-aware planning principles can be applied to individual outbreaks to estimate downstream impacts on military healthcare systems and operational readiness.
MORALE™: Military Outbreak Recovery Assessment for Long-term Effects
The recent influenza outbreak among military trainees illustrates an important limitation of traditional outbreak surveillance. Public health systems rapidly measure infections, hospitalizations, mortality, and transmission dynamics, providing essential information for outbreak control and force health protection. Yet once an outbreak subsides, relatively little information is routinely collected about how many affected individuals experience delayed recovery, persistent symptoms, reduced physical performance, or transition into longer-term post-infectious illness (Choutka et al., 2022; Davis et al., 2023; National Academies of Sciences, Engineering, and Medicine, 2024).
To address this planning gap, CYNAERA developed MORALE™ (Military Outbreak Recovery Assessment for Long-term Effects). MORALE™ is a recovery forecasting framework designed specifically for military populations. Rather than replacing traditional outbreak surveillance, it extends existing military public health practice by estimating the downstream recovery population that may emerge following infectious disease outbreaks in recruit training centers, military installations, deployed environments, academies, and other operational settings. This approach complements growing recognition that recovery itself represents an important public health outcome alongside infection, hospitalization, and mortality (Al-Aly et al., 2024; Peluso et al., 2023).
At its core, MORALE™ applies a simple planning equation:
Estimated Recovery Population = Estimated Outbreak Infections × Recovery Probability
Recovery can then be projected across multiple time horizons.
30-Day Delayed Recovery = Estimated Outbreak Infections × Delayed Recovery Probability
90-Day Persistent Recovery = Estimated Outbreak Infections × Persistent Recovery Probability
Long-Term Post-Infectious Illness = Estimated Outbreak Infections × Long-Term Conversion Probability
Unlike US-CCUC™, which estimates the hidden population already living with chronic illness, MORALE™ is prospective. It estimates the recovery population likely to emerge following a specific outbreak, allowing military planners to anticipate downstream healthcare utilization, rehabilitation needs, temporary duty limitations, specialty referrals, workforce impacts, and operational readiness before those demands fully materialize.
To illustrate the concept, conservative planning assumptions are applied to the recent influenza outbreak at Joint Base San Antonio-Lackland, where public reporting identified approximately 275 confirmed influenza cases, four hospitalizations, and one recruit death under investigation (ABC News, 2026; Associated Press, 2026; CIDRAP, 2026).
Estimated Outbreak Infections | 30-Day Delayed Recovery (5%) | 90-Day Persistent Recovery (2%) | Long-Term Post-Infectious Illness (1%) |
275 confirmed cases | ~14 individuals | ~6 individuals | ~3 individuals |
500 estimated infections | ~25 individuals | ~10 individuals | ~5 individuals |
1,000 estimated infections | ~50 individuals | ~20 individuals | ~10 individuals |
5,000 estimated infections | ~250 individuals | ~100 individuals | ~50 individuals |
These values represent illustrative planning estimates rather than validated clinical probabilities. Their purpose is to demonstrate how even conservative assumptions generate meaningful recovery populations following relatively modest outbreaks. Future versions of MORALE™ may calibrate these probabilities using longitudinal military health surveillance, Defense Health Agency datasets, electronic health records, wearable physiological monitoring, rehabilitation utilization, and prospective cohort studies.
Although the projected number of long-term cases may appear small, their operational significance can be substantial. Military organizations must plan not only for direct medical care, but also for delayed graduation, temporary duty restrictions, rehabilitation services, reduced deployability, replacement training, and the cumulative effects of diminished unit readiness. Recovery forecasting therefore provides an additional layer of operational intelligence that complements traditional outbreak response rather than replacing it (Defense Health Agency, 2023; Institute of Medicine, 2007).
MORALE™ also serves as the first operational implementation of REVIVE™ (Recovery Evaluation and Visibility for Infection and Viral Events), CYNAERA's broader recovery forecasting framework. While REVIVE™ is designed to estimate recovery populations across civilian infectious disease outbreaks, MORALE™ adapts those same principles to the unique planning requirements of military medicine and operational readiness.
Together, US-CCUC™ Influenza and MORALE™ extend disease intelligence across the full continuum of infectious disease response. US-CCUC™ estimates the hidden population already living with Long Flu, while MORALE™ forecasts the recovery population that may emerge after the next outbreak. Rather than measuring only who becomes infected, recovery-aware surveillance asks an additional question that may become increasingly important for future preparedness: How many people will still need care after the outbreak is over?
What Can Long COVID Teach Us About Long Flu?
US-CCUC™ Influenza is intended to serve as the first step toward a recovery-aware model of influenza surveillance rather than a final prevalence estimate. Like the broader US-CCUC™ framework, its strength lies in its ability to evolve as new evidence becomes available. Future iterations may incorporate longitudinal electronic health record analyses, insurance claims data, military surveillance systems, wearable device metrics, patient-reported outcomes, biomarker studies, and prospective cohort data to refine estimates of persistence, recovery, and long-term health trajectories.
An important next step will be identifying which individuals are most likely to experience prolonged recovery following influenza infection. Age, viral strain, vaccination history, reinfection, pre-existing infection-associated chronic conditions, immune status, environmental exposures, socioeconomic factors, and physiological reserve may all influence recovery trajectories (Al-Aly et al., 2024; Choutka et al., 2022; Peluso et al., 2023). Better understanding these interactions could allow healthcare systems to move beyond estimating prevalence and begin identifying patients who may benefit from early monitoring, rehabilitation, or preventive intervention.
The framework also has applications beyond seasonal influenza. Respiratory syncytial virus (RSV), Epstein-Barr virus, adenovirus, enteroviruses, Lyme disease, Q fever, dengue, chikungunya, Ebola virus disease, and future emerging pathogens all raise similar questions regarding persistent health effects after acute infection (Choutka et al., 2022). Rather than developing separate surveillance correction methods for each condition, US-CCUC™ provides a scalable architecture that can be adapted across infection-associated chronic conditions while maintaining consistent epidemiologic principles.
Within the broader CYNAERA ecosystem, future integration with the Primary Chronic Trigger (PCT™) Framework, Stage Zero™, Adaptive Reserve Collapse™ (ARC™), Diagnostic Multiplier™, and related frameworks may improve understanding of why some individuals recover rapidly while others transition toward chronic illness. Together, these complementary frameworks offer a systems-based approach to studying infection-associated chronic conditions across the full continuum from acute infection through long-term recovery.
From Infection to Recovery: What Usually Gets Measured?
During Acute Influenza | After Acute Influenza |
Infections | Persistent symptoms |
Hospitalizations | Functional recovery |
ICU admissions | Chronic illness |
Deaths | Return to baseline |
Routinely monitored | Rarely monitored |
Counted in surveillance | Estimated using US-CCUC™ |
As public health increasingly recognizes that infectious diseases may produce health consequences extending well beyond viral clearance, surveillance systems will likely continue evolving. Measuring infections, hospitalizations, and mortality will remain essential, but future preparedness may also require routine measurement of recovery, functional outcomes, and persistent health impairment. US-CCUC™ Influenza represents one practical approach toward that broader recovery-aware model of surveillance.
What's Next for Long Flu Research?
US-CCUC™ Influenza represents the first step toward a recovery-aware model of influenza surveillance rather than a final prevalence estimate. Like the broader US-CCUC™ framework, its strength lies in its ability to evolve as new evidence becomes available. Future iterations may incorporate longitudinal electronic health record analyses, insurance claims data, military health surveillance systems, wearable device metrics, patient-reported outcomes, biomarker studies, environmental exposure data, wastewater surveillance, genomic surveillance, and prospective cohort research to refine estimates of persistence, recovery, and long-term health trajectories (Reed et al., 2015; Choutka et al., 2022; National Academies of Sciences, Engineering, and Medicine, 2024).
An equally important next step will be identifying which individuals are most likely to experience prolonged recovery following influenza infection. Age, viral strain, vaccination history, reinfection, pre-existing infection-associated chronic conditions, immune status, environmental exposures, socioeconomic factors, and physiological reserve may all influence recovery trajectories (Al-Aly et al., 2024; Choutka et al., 2022; Peluso et al., 2023). Better understanding these interactions could allow healthcare systems to move beyond estimating prevalence and begin identifying individuals who may benefit from earlier monitoring, rehabilitation, targeted intervention, or preventive care.
The next evolution of this work is REVIVE™ (Recovery Evaluation and Visibility for Infection and Viral Events), a recovery forecasting framework designed to estimate the downstream health impact of infectious disease outbreaks before persistent illness accumulates within healthcare systems. While US-CCUC™ Influenza estimates the hidden population already living with Long Flu, REVIVE™ extends disease intelligence into the future by forecasting expected recovery populations following influenza, RSV, COVID-19, norovirus, Epstein-Barr virus, Lyme disease, dengue, and future emerging infectious threats. Within military environments, MORALE™ (Military Outbreak Recovery Assessment for Long-term Effects) represents the first operational implementation of REVIVE™, translating outbreak surveillance into readiness-focused recovery planning.
US-CCUC™ Influenza also serves as one component of CYNAERA's broader Disease Intelligence ecosystem. Rather than functioning as an isolated prevalence model, it complements a growing family of interoperable frameworks designed to study infection-associated chronic conditions across the entire continuum of illness.
The Primary Chronic Trigger (PCT™) Framework identifies infectious, environmental, and physiological events capable of initiating chronic disease. Stage Zero™ characterizes the period of measurable physiological instability that may precede formal diagnosis, creating opportunities for earlier recognition. Adaptive Reserve Collapse™ (ARC™) models how cumulative biological stress progressively reduces resilience and recovery capacity over time. Diagnostic Multiplier™ estimates populations likely to remain undiagnosed despite ongoing healthcare utilization, while Pathos™ evaluates biological and clinical similarity across chronic diseases to identify shared mechanisms and therapeutic opportunities (Adinig, PCT Framework, 2026; Adinig, US-CCUC, 2026).
Additional CYNAERA frameworks expand this systems-based approach. VitalGuard™ evaluates environmental and contextual factors that influence symptom stability and recovery. SymCas™ models symptom cascade dynamics and multisystem interactions following infectious or environmental triggers. Therapeutic Polarity™ explores how treatment effectiveness may vary according to disease state, timing, and underlying biological terrain.
Together, these complementary frameworks seek to transform fragmented observations into an integrated understanding of disease progression, recovery, resilience, and intervention.
CYNAERA Framework | Primary Role in Long Flu Research |
US-CCUC™ Influenza | Estimates the hidden population currently living with Long Flu. |
REVIVE™ | Forecasts future recovery populations following infectious disease outbreaks. |
MORALE™ | Applies REVIVE™ to military outbreaks and operational readiness planning. |
PCT™ Framework | Identifies infectious and environmental triggers that initiate chronic illness. |
Stage Zero™ | Detects early physiological instability before formal diagnosis. |
ARC™ | Models declining recovery capacity following cumulative biological stress. |
Diagnostic Multiplier™ | Estimates hidden and undiagnosed patient populations. |
Pathos™ | Compares Long Flu with Long COVID, ME/CFS, dysautonomia, Lyme disease, and other infection-associated chronic conditions. |
VitalGuard™ | Evaluates environmental factors that influence recovery and symptom stability. |
SymCas™ | Maps symptom cascade dynamics across multiple organ systems. |
Therapeutic Polarity™ | Evaluates how treatment response changes across different stages of illness. |
Beyond seasonal influenza, these frameworks provide a scalable methodology that can be adapted across a broad spectrum of infection-associated chronic conditions. Rather than developing separate surveillance correction models for every pathogen, the CYNAERA Disease Intelligence ecosystem applies a common analytical architecture while allowing disease-specific assumptions, biological evidence, and recovery parameters to evolve as new research becomes available.
As public health increasingly recognizes that infectious diseases produce consequences extending well beyond viral clearance, surveillance systems will likely continue evolving. Measuring infections, hospitalizations, and mortality will remain essential, but future preparedness may also require routine measurement of recovery, physiological reserve, functional outcomes, environmental influences, long-term healthcare utilization, and persistent health impairment.
Viewed collectively, the CYNAERA Disease Intelligence ecosystem represents a shift from measuring infectious diseases as isolated clinical events toward understanding recovery as a measurable public health outcome. Within that ecosystem, US-CCUC™ provides population intelligence, REVIVE™ provides recovery forecasting, and MORALE™ translates those forecasts into operational planning. Together, these frameworks support a more comprehensive approach to healthcare planning, military readiness, research prioritization, and pandemic preparedness.
Conclusion
Influenza has long been recognized as a major cause of seasonal respiratory illness, hospitalization, and mortality. Growing historical and contemporary evidence suggests, however, that its impact does not necessarily end when acute infection resolves. A proportion of individuals appear to experience persistent fatigue, cognitive dysfunction, autonomic symptoms, exercise intolerance, respiratory impairment, and other long-term health consequences that remain largely invisible within conventional influenza surveillance systems (Choutka et al., 2022; Davis et al., 2023; Al-Aly et al., 2024).
Using the United States Chronic Condition Undercount Correction (US-CCUC™) methodology, this paper presents a practical framework for estimating the hidden population living with persistent post-influenza chronic illness. By distinguishing between the historical pre-pandemic period and the contemporary post-pandemic environment, the framework recognizes that influenza now circulates within a substantially different biological landscape shaped by Long COVID and the broader expansion of infection-associated chronic conditions (Adinig, US-CCUC, 2026; Adinig, PCT Framework, 2026).
Under conservative planning assumptions, approximately 600,000 to 900,000 Americans may have been living with persistent post-influenza chronic illness before 2020. Today, that planning population may have increased to approximately 1.2 to 1.8 million Americans. Applying evidence-informed healthcare planning assumptions suggests this hidden population could represent approximately $6 billion to $27 billion in annual healthcare and economic impact, demonstrating how even modest rates of prolonged recovery can translate into substantial healthcare demand when seasonal influenza affects tens of millions of Americans each year.
This paper also introduces MORALE™ (Military Outbreak Recovery Assessment for Long-term Effects) as a complementary recovery forecasting framework. Whereas US-CCUC™ estimates the hidden population already living with Long Flu, MORALE™ estimates the recovery population that may emerge following individual outbreaks. Together, these complementary frameworks extend disease intelligence beyond counting infections toward anticipating long-term recovery needs before they accumulate within healthcare systems or affect military readiness.
More broadly, this work reflects an evolution in how infectious diseases may be measured. Traditional surveillance has appropriately emphasized infections, hospitalizations, and mortality because these outcomes are essential for outbreak response. The experience of Long COVID has demonstrated, however, that these measures alone may not fully capture the long-term consequences of infectious disease. Recovery itself should increasingly be viewed as a measurable public health outcome worthy of routine surveillance, research investment, and healthcare planning (National Academies of Sciences, Engineering, and Medicine, 2024; Choutka et al., 2022).
US-CCUC™ Influenza is not intended to replace existing influenza surveillance. Rather, it complements established public health systems by extending observation beyond acute infection to estimate the hidden population living with persistent illness after influenza. As understanding of infection-associated chronic conditions continues to evolve, recovery-aware surveillance may become an increasingly important component of healthcare planning, military readiness, workforce forecasting, disability policy, and future pandemic preparedness.
Ultimately, measuring how many people become infected is only part of understanding the true impact of infectious disease. The future of infectious disease surveillance will not be defined solely by how well we count infections, but by how well we understand recovery.
Frequently Asked Questions (FAQ)
What Is Long Flu?
Throughout this paper, Long Flu refers broadly to persistent post-influenza chronic illness, meaning ongoing health impairment that continues after the acute influenza infection has resolved. Symptoms may include fatigue, exercise intolerance, cognitive dysfunction, autonomic symptoms, respiratory limitations, sleep disturbance, chronic pain, or reduced functional capacity. Long Flu is used here as a public-facing term rather than a formal medical diagnosis and may include individuals who later receive diagnoses such as ME/CFS, dysautonomia, post-viral syndrome, or other infection-associated chronic conditions.
Can the Flu Cause Long-Term Health Problems?
Yes. Historical medical literature and contemporary research have documented that a subset of individuals experience persistent symptoms following influenza infection. While most people recover completely, some develop prolonged fatigue, neurological symptoms, respiratory impairment, or multisystem illness that extends well beyond the acute infection.
Is Long Flu the Same as Long COVID?
No. Long Flu and Long COVID are associated with different viruses and should not be considered equivalent conditions. However, both demonstrate that acute viral infections can lead to prolonged multisystem illness in a subset of individuals. This paper examines Long Flu as part of the broader family of infection-associated chronic conditions (IACCs).
How Many Americans May Be Living With Long Flu?
Using the US-CCUC™ Influenza framework, this paper estimates that approximately 600,000 to 900,000 Americans were living with persistent post-influenza chronic illness before the COVID-19 pandemic. Under contemporary post-pandemic conditions, the estimated planning population increases to approximately 1.2 to 1.8 million Americans.
Why Does This Paper Estimate Two Different Long Flu Populations?
The paper separates historical (pre-2020) and contemporary (post-2020) estimates because the biological landscape has changed substantially following the COVID-19 pandemic. Millions of Americans now live with Long COVID and other infection-associated chronic conditions that may influence recovery following subsequent influenza infections.
Why Has Long Flu Been Difficult to Recognize?
Traditional influenza surveillance focuses primarily on infections, hospitalizations, and mortality. Once the acute illness resolves, routine surveillance rarely follows patients long enough to determine whether they return fully to their previous physiological baseline. Patients with persistent symptoms often receive care across multiple medical specialties, making the long-term burden difficult to recognize through conventional surveillance systems.
What Is US-CCUC™ Influenza?
US-CCUC™ Influenza is CYNAERA's United States Chronic Condition Undercount Correction framework adapted specifically for influenza. Rather than relying on a single data source, it integrates influenza burden estimates, longitudinal studies, healthcare utilization data, patient-reported outcomes, and biological evidence to estimate the hidden population living with persistent post-influenza chronic illness.
Does This Mean Influenza Has Become More Dangerous?
No. This paper does not argue that influenza itself has fundamentally changed. Instead, it proposes that influenza now circulates within a population that has changed substantially following the COVID-19 pandemic, including millions of individuals living with Long COVID, ME/CFS, dysautonomia, autoimmune disease, and other infection-associated chronic conditions.
Why Does Estimating Long Flu Matter?
Even if only a small percentage of influenza infections result in prolonged illness, seasonal influenza affects tens of millions of Americans each year. Small differences in recovery rates can therefore translate into hundreds of thousands of additional individuals requiring ongoing healthcare, rehabilitation, workplace accommodations, disability evaluation, specialty care, or military medical services.
How Does the Recent Military Influenza Outbreak Relate to Long Flu?
The recent outbreak among military trainees demonstrates how effectively public health systems detect and respond to acute influenza. It also highlights an unanswered question: how many affected individuals will continue experiencing health consequences weeks or months after the outbreak has ended? US-CCUC™ Influenza was developed to help estimate that hidden recovery population.
Can US-CCUC™ Be Used for Other Diseases?
Yes. Although this paper focuses on influenza, the broader US-CCUC™ methodology can be adapted to estimate hidden prevalence across other infection-associated chronic conditions, including Long COVID, ME/CFS, respiratory syncytial virus (RSV), Epstein-Barr virus, Lyme disease, Q fever, dengue, chikungunya, and future emerging infectious diseases.
CYNAERA Framework Papers and Core Research Libraries
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library, ME/CFS Library, Lyme Library, Autoimmune Library and CRISPR Remission Library are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.
Licensing and Integration
CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.
About the Author
Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.
Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey, Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.
She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.
Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.
References
ABC News. (2026). Flu outbreak among Air Force recruits at Joint Base San Antonio-Lackland. https://abcnews.go.com/Health/flu-outbreak-air-force-recruits-joint-base-san/story?id=133994394
Adinig, C. (2026). ME/CFS Prevalence in the Long COVID Era: A Corrected U.S. Burden Estimate Using Infection-Associated Chronic Condition Modeling. SSRN. https://doi.org/10.2139/ssrn.6835159
Adinig, C. (2026). Post-Exertional Malaise as Threshold-Dependent Systems Failure: A Multi-Domain Load Model for Intervention Timing and Trial Design in ME/CFS. SSRN. https://doi.org/10.2139/ssrn.6875522
Adinig, C. (2026). The Primary Chronic Trigger Framework: A Mathematical Blueprint for Detecting Ignition Events and Modeling Burden in Infection-Associated Chronic Conditions. SSRN. https://doi.org/10.2139/ssrn.6892100
Adinig, C. (2026). Stage Zero: Preclinical Immune and Autonomic Instability Preceding Infection-Associated Chronic Conditions. SSRN. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=6903458
Adinig, C. (2026). SymCas: Symptom Cascade Dynamics Across Infection-Associated Chronic Conditions. SSRN. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=6911221
Adinig, C. (2026). VitalGuard: Environmental Flare Risk Framework. SSRN. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=6848063
Adinig, C. (2026). US-CCUC: Correcting Surveillance-Based Prevalence Undercounting Across Infection-Associated Chronic Conditions. SSRN. https://doi.org/10.2139/ssrn.6967838
Adinig, C. (2026). Long COVID Prevalence in U.S. Military and Veteran Populations: Corrected National Estimates Using US-CCUC Military. CYNAERA Institute.
Adinig, C. (2026). PCT Military: A Framework for Detecting Ignition Events and Modeling IACC Burden in U.S. Deployments. CYNAERA Institute.
Associated Press. (2026). Military restores mandatory flu vaccinations after outbreak among recruits. https://apnews.com/article/4255f063ef99ea2d00cb24fec8793c32
Centers for Disease Control and Prevention. (2025). Disease Burden of Influenza. https://www.cdc.gov/flu-burden/php/about/index.html
Centers for Disease Control and Prevention. (2026). Estimated Influenza Burden. https://www.cdc.gov/flu-burden/php/about/index.html
Choutka, J., Jansari, V., Hornig, M., and Iwasaki, A. (2022). Unexplained post-acute infection syndromes. Nature Medicine, 28(5), 911-923. https://doi.org/10.1038/s41591-022-01810-6
CIDRAP. (2026). Quick Takes: More Air Force Flu Cases, Soft Cheese Listeria Outbreak Grows. https://www.cidrap.umn.edu/influenza-general/quick-takes-more-air-force-flu-cases-soft-cheese-listeria-outbreak-grows-flucovid
Davis, H. E., Assaf, G. S., McCorkell, L., et al. (2021). Characterizing Long COVID in an international cohort: Seven months of symptoms and their impact. EClinicalMedicine, 38, 101019. https://doi.org/10.1016/j.eclinm.2021.101019
Davis, H. E., McCorkell, L., Vogel, J. M., and Topol, E. J. (2023). Long COVID: Major findings, mechanisms and recommendations. Nature Reviews Microbiology, 21(3), 133-146. https://doi.org/10.1038/s41579-022-00846-2
Defense Health Agency. (2023). Force Health Protection Guidance. https://health.mil
Institute of Medicine. (2007). Gulf War and Health: Volume 6. Physiologic, Psychologic, and Psychosocial Effects of Deployment-Related Stress. National Academies Press. https://doi.org/10.17226/11922
Institute of Medicine. (2015). Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. National Academies Press. https://doi.org/10.17226/19012
Iuliano, A. D., Roguski, K. M., Chang, H. H., et al. (2018). Estimates of global seasonal influenza-associated respiratory mortality: A modelling study. The Lancet, 391(10127), 1285-1300. https://doi.org/10.1016/S0140-6736(17)33293-2
Komaroff, A. L., and Lipkin, W. I. (2023). Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of Long COVID. Trends in Molecular Medicine, 29(8), 689-692. https://doi.org/10.1016/j.molmed.2023.04.002
National Academies of Sciences, Engineering, and Medicine. (2024). Long-Term Health Effects of COVID-19: Disability Assessment Challenges and Opportunities. National Academies Press. https://doi.org/10.17226/27756
Peluso, M. J., Deeks, S. G., and Henrich, T. J. (2023). The immunology of Long COVID. Nature Reviews Immunology. https://doi.org/10.1038/s41577-023-00904-7
Reed, C., Chaves, S. S., Daily Kirley, P., et al. (2015). Estimating influenza disease burden from population-based surveillance data in the United States. PLoS ONE, 10(3), e0118369. https://doi.org/10.1371/journal.pone.0118369
Xie, Y., Choi, T., and Al-Aly, Z. (2024). Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: A cohort study. The Lancet Infectious Diseases. https://doi.org/10.1016/S1473-3099(24)00176-5
Comments